Swatch Group: how long till break-up?

(Full access for Members only)

Swatch Group: how long till break-up?

9 December 2022

Profitable, cash-rich companies can ignore market trends – but only ever for so long.

Swatch Group is a collection of incredible brands and assets, but the market is sceptical about their outlook. Since 2013, the stock has lost 58% of its value. Its main competitors have all made up ground since. LVMH is up 450%, Kering gained 200%, and even industry-laggard Richemont rose 30%.

Swatch Group stock is now cheap not just in relative but also absolute terms. It trades at an EV/EBITDA multiple of 7. The Omega brand alone, which contributes 35% to group revenue, could be worth almost the entire enterprise value if restructured and sold separately.

The family heirs are an issue. They control 43% of the shares, dominate the board, and are protected by voting right restrictions for outsiders.

Right now, the market assumes there is ZERO chance of things changing at Swatch Group. However, broader industry trends and the advancing age of family members may catalyse change during the next 24 months.

A change in leadership, the sale of individual divisions or brands, and even a break-up of the company all seem possible. Just the expectation of possible change should see the share price jump – the stock's low valuation makes it akin to a coiled spring. Swatch Group's profitability and strong balance sheet make it a defensive investment with a lot of upside potential.

This 34-page report takes you on a journey through the fascinating world of the Swiss luxury watch industry.

Not a Member yet? Sign up for a Membership - just USD 49/year.
Already a Member? Log into your account to download the report.

Most recent

Sark – it’s not a big deal

Sark – it’s not a big deal

I had mobilised GBP 30m to buy a portfolio of real estate in Sark, with plans to IPO the company. How did it go, and what may happen next?

read more

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.